Prescribing for Helicobacter pylori 幽門螺旋桿菌 in Taiwan

2025 04 06 Owen Yang

Following the report of a still high Helicobacter pylori prevalence in Taiwan ( 28%, declining), one would expect a high number of eradication therapy. There has not been mush change of Helicobacter eradication regimes during 2005-2020, typically involving Amoxicillin (#J01CA04), Clarithromycin (#J01FA09), Metronidazole (currently under 'Anti-protozoals', #P01), and a Proton-pump inhibitor (#A02BC). There are other indications of these medications, but judging from the prescribing of Clarithromycin (#J01FA09), prescribing for this indication may not be high.

Vonoprazon (#A02BC08), a potassium-competitive acid blocker, is a new drug in line to potentially replace PPIs. In Prescribing in Taiwan it will technically be under the same category with PPIs, but so far it is not prescribed under the National Health Insurance.